Cyclerion rises on promising pre-clinical data for lead candidate
17/06/2022 15:08
** Shares of drug developer Cyclerion Therapeutics CYCN.O
rise ~6% to $0.50 premarket
** Co says in preclinical studies its lead candidate was
associated with improved cellular energetics and reduced
inflammation in mitochondrial disease urn:newsml:reuters.com:*:nGNX10nsbX
** Data provides support for ongoing CY6463 clinical studies
in central nervous system diseases associated with mitochondrial
dysfunction - co
** Both analysts covering the stock rate it "buy"; their
median PT is $9
** Including session moves, stock down ~70.9% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))